On November 23, the application for the Bayer prostate cancer new drug Xofigo (Rainium Chloride [223Ra] Injection) was officially accepted by CDE. Xofigo was first approved by the FDA on May 15, 2013 for the treatment of advanced bone metastases in castration-resistant prostate cancer. In the Phase 3 ALSYMPCA… Continue Reading Bayer prostate cancer new drug Xofigo applied for listing in China